EYPT Q3 2019 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+416.3% YoY

Gross Profit

$2M87.0% margin

Operating Income

-$14M-560.4% margin

Net Income

-$16M-623.6% margin

EPS (Diluted)

$-1.46

QoQ Revenue Growth

-65.2%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$977,000

Balance Sheet

Total Assets

$79M

Total Liabilities

$63M

Stockholders' Equity

$16M

Cash & Equivalents

$32M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$486,000	+416.3%
Gross Profit	$2M	-$6M	+138.0%
Operating Income	-$14M	-$14M	-3.7%
Net Income	-$16M	-$33M	+52.8%

Revenue Segments

D E X Y C U Product

$954,00095%

Y U T I Q Product

$55,0005%